Verve Therapeutics paused a gene-editing trial (Heart-1) targeting cholesterol reduction due to alarming side effects in a patient, including abnormal liver enzymes and thrombocytopenia.
Familial hypercholesterolemia, a genetic disorder causing LDL buildup, significantly elevates heart attack risk, lowering patient life expectancy.
#verve-therapeutics #gene-editing-trial #familial-hypercholesterolemia #cholesterol #heart-attack-risk
[
add
]
[
|
|
...
]